MedTrace Logo

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

NCT00389090 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-02-09

No results posted yet for this study

Summary

This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.

Conditions

Interventions

DRUG

Temozolomide and O6-Benzylguanine

O6BG + Temozolomide

Sponsors & Collaborators

  • Keryx / AOI Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Jennifer Quinn, MD · Preston Robert Tisch Brain Tumor Center at Duke

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-06-30
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389090 on ClinicalTrials.gov